Literature DB >> 15102590

Dronedarone: an amiodarone analogue.

Sheila A Doggrell1, Jules C Hancox.   

Abstract

Of the antiarrhythmic drugs in current use, amiodarone is one of the most effective and is associated with a comparatively low risk of drug-induced pro-arrhythmia, probably due to its multiple pharmacological actions on cardiac ion channels and receptors. However, amiodarone is associated with significant extra-cardiac side effects and this has driven development of amiodarone analogues. These analogues include short acting analogues (e.g., AT-2001) with similar acute effects to amiodarone, the thyroid receptor antagonist KB-130015 and dronedarone. Dronedarone, (SR-33589; Sanofi-Synthelabo), is a non-iodinated amiodarone derivative that inhibits Na +, K + and Ca 2+ currents. It is a potent inhibitor of the acetylcholine-activated K + current from atrial and sinoatrial nodal tissue, and inhibits the rapid delayed rectifier more potently than slow and inward rectifier K + currents and inhibits L-type calcium current. Dronedarone is an antagonist at alpha- and beta-adrenoceptors and unlike amiodarone, has little effect at thyroid receptors. Dronedarone is more potent than amiodarone in inhibiting arrhythmias and death in animal models of ischaemia- and reperfusion-induced arrhythmias. In the Dronedarone Atrial Fibrillation Study After Electrical Cardioversion (DAFNE) clinical trial, dronedarone 800 mg/day appeared to be effective and safe for the prevention of atrial fibrillation relapses after cardioversion. The Antiarrhythmic Trial with Dronedarone in Moderate-to-Severe Congestive Heart Failure Evaluating Morbidity Decrease (ANDROMEDA) trial was stopped due to a potential increased risk of death in the dronedarone group. Trials of dronedarone in the maintenance of sinus rhythm in patients with atrial fibrillation and a safety and tolerability study in patients with an implantable cardioverter defibrillator are ongoing. Further experimental and clinical studies are required before we have a definitive answer to whether dronedarone has advantages over amiodarone and other amiodarone analogues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102590     DOI: 10.1517/13543784.13.4.415

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  6 in total

1.  Effect of dronedarone on Na+, Ca2+ and HCN channels.

Authors:  Roman Bogdan; Heinz Goegelein; Hartmut Ruetten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-29       Impact factor: 3.000

Review 2.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 3.  [Dronedarone: the new antiarrythmic agent?].

Authors:  J Brachmann; A-M Sinha
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-06

Review 4.  [New developments in the antiarrhythmic therapy of atrial fibrillation].

Authors:  Ursula Ravens
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-02-05

5.  Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes.

Authors:  Yasuhide Watanabe; Junko Kimura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-08       Impact factor: 3.000

6.  Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone.

Authors:  T A Meléndez; A Huanosta-Gutiérrez; C Barriga-Montoya; M González-Andrade; F Gómez-Lagunas
Journal:  Pflugers Arch       Date:  2020-01-02       Impact factor: 3.657

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.